A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

Abstract Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop ne...

Full description

Bibliographic Details
Main Authors: Yuexian Zhou, Huifang Zong, Lei Han, Yueqing Xie, Hua Jiang, John Gilly, Baohong Zhang, Huili Lu, Jie Chen, Rui Sun, Zhidi Pan, Jianwei Zhu
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Bispecific antibody
CD3
PRLR
Breast cancer
Online Access:http://link.springer.com/article/10.1186/s13046-020-01564-4

Internet

http://link.springer.com/article/10.1186/s13046-020-01564-4

Similar Items